COVID-19 IP Catch-Up: Source Code Woes, Generic Antivirals
The Federal Circuit will continue to hold remote oral arguments into the summer, Gilead is allowing some generic-drug makers to produce versions of its antiviral treatment remdesivir, and companies that are...To view the full article, register now.
Already a subscriber? Click here to view full article